Insider Buying: GSK (LON:GSK) Insider Buys £126.21 in Stock

GSK plc (LON:GSK) insider Julie Brown purchased 7 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were purchased at an average price of GBX 1,803 per share, for a total transaction of £126.21.

GSK Stock Performance

GSK stock opened at GBX 1,770.50 on Monday. The business has a 50-day moving average price of GBX 1,901.77 and a 200 day moving average price of GBX 1,966.46. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The company has a market capitalization of £70.94 billion, a P/E ratio of 15.03, a PEG ratio of 1.24 and a beta of 0.29. GSK plc has a 1-year low of GBX 1,455 and a 1-year high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research report on Tuesday, September 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of GBX 2,039.38.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Japan’s Ministry of Health approved a prefilled, ready-to-use presentation of GSK’s Shingrix shingles vaccine. The format could improve convenience for healthcare providers and support Shingrix adoption in an important market. Japan MHLW approves GSK prefilled Shingrix presentation
• Positive Sentiment: GSK is advancing its experimental mRNA seasonal flu vaccine into late-stage development after mid-stage results showed stronger immune responses than standard- and high-dose approved flu vaccines in younger and older adults. Success in late-stage trials could create a meaningful future growth opportunity, though clinical and regulatory risks remain. GSK mRNA flu vaccine development
• Neutral Sentiment: Several GSK executives acquired small amounts of stock under the company’s reward plan, including Julie Brown’s purchase of seven shares worth approximately £126. The transactions signal alignment with shareholders but are too small to represent a major investment signal. GSK executives acquire shares
• Neutral Sentiment: RBC reiterated its “Sector Perform” rating, indicating a balanced view rather than a strong bullish or bearish stance. Other brokerages have set an average target of about GBX 2,048.57, above the recent trading level. RBC reiterates GSK Sector Perform rating
• Negative Sentiment: Commentary highlighting that GSK trades below levels seen decades ago reflects continuing investor concerns about valuation, growth expectations and the company’s ability to overcome past challenges. This sentiment may be weighing on the shares despite the positive vaccine developments. Analysis of GSK share price

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.